Company Description
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally.
The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment.
It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com.
Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
| Country | United States |
| Founded | 2009 |
| IPO Date | Apr 5, 2019 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Ms. Janet Hall |
Contact Details
Address: 2925 Richmond Avenue, Suite 1200 Houston, Texas 77098 United States | |
| Phone | (800) 873-5141 |
| Website | guardionhealth.com |
Stock Details
| Ticker Symbol | GHSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001642375 |
| CUSIP Number | 40145Q203 |
| ISIN Number | US40145Q5009 |
| Employer ID | 47-4428421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Janet Hall | President and Chief Executive Officer |
| Robert Neal Weingarten | Independent Chairman and Secretary |
| Craig J. Sheehan | Chief Commercial Officer |
| Katie Cox | Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 15, 2024 | 8-K | Current Report |
| Jun 6, 2024 | 8-K | Current Report |
| May 23, 2024 | SCHEDULE 13G/A | Filing |
| May 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 23, 2024 | 8-K | Current Report |
| May 21, 2024 | 8-K | Current Report |
| May 21, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 15, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 15, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |